[{"id":"cb41102b-0fb2-48d9-9bc0-4853a675d51c","acronym":"ELUCIDATE","url":"https://clinicaltrials.gov/study/NCT05985655","created_at":"2023-08-14T16:10:12.231Z","updated_at":"2024-07-02T16:35:16.495Z","phase":"Phase 1/2","brief_title":"Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05985655 - ELUCIDATE","lead_sponsor":"Exscientia AI Limited","biomarkers":" HER-2 • CDK6 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CDK6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-617"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-03-05"}]